GlassScriptPhysician profile
Weiran Cao
NPI 1720315443
$6,662.20
in general payments reported to CMS, 2019-2025
36 companies · $789 in 2025
The $789 reported for 2025 was more than what 81% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,527 · 2022: $1,200 · 2023: $1,699 · 2024: $1,447 · 2025: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,935.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,934.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $902.80 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $728.02 | 2022-2025 | |
| Novo Nordisk INC | $724.24 | 2021-2025 | Rybelsus, Ozempic |
| Amgen INC. | $629.75 | 2021-2025 | Evenity, Prolia, Prolia |
| Glaxosmithkline, LLC. | $557.60 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $517.88 | 2021-2025 | Jardiance |
| Radius Health, INC. | $258.16 | 2021-2025 | Tymlos |
| Ironwood Pharmaceuticals, INC | $210.80 | 2021-2024 | Linzess |
| Esperion Therapeutics, INC. | $153.83 | 2021-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $152.11 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $149.42 | 2021 | |
| Amarin Pharma, INC. | $142.14 | 2021 | |
| Exact Sciences Corporation | $137.54 | 2024-2025 | Cologuard Collection Kit |
| Scilex Pharmaceuticals INC. | $119.03 | 2021-2024 | Ztlido |
| Nestle Healthcare Nutrition INC. | $111.38 | 2021-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $110.24 | 2021-2025 | Airsupra, Farxiga |
| Sumitomo Pharma America, INC. | $109.95 | 2023-2024 | Gemtesa |
| Redhill Biopharma INC. | $109.02 | 2022-2024 | Talicia |
| Dexcom, INC. | $92.92 | 2021-2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $92.54 | 2021-2022 | |
| Astellas Pharma US INC | $74.13 | 2021-2022 | |
| Abbvie INC. | $71.09 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.74 | 2021-2023 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $58.69 | 2023-2025 | Rexulti |
| Aimmune Therapeutics, INC. | $53.76 | 2024-2025 | Zenpep |
| Pfizer INC. | $46.27 | 2022-2023 | |
| Vivus LLC | $45.35 | 2022-2023 | Pancreaze |
| Sunovion Pharmaceuticals INC. | $41.24 | 2022 | |
| Phathom Pharmaceuticals, INC. | $35.86 | 2024 | Voquezna |
| Corium, LLC | $30.27 | 2023 | Adlarity |
| Alvogen INC | $27.13 | 2023 | Teriparatide |
| Almatica Pharma LLC | $25.43 | 2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $24.66 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $21.22 | 2023 | Livalo, Seglentis |
| Biogen, INC. | $17.70 | 2021 | |
| Xeris Pharmaceuticals, INC. | $16.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weiran Cao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.